SCHEMBL24254972

SCHEMBL24254972

COC(OC)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 7/20 0.48
ALDH1A1 P00352 5/20 0.48
AOC3 Q16853 1/20 0.45
SIGMAR1 Q99720 1/20 0.43
ADRA2B P18089 2/20 0.42
ADRA2C P18825 2/20 0.42
SLC6A2 P23975 2/20 0.42
HTR2A P28223 2/20 0.42
ADRA1A P35348 2/20 0.42
SLC6A3 Q01959 2/20 0.42
KCNH2 Q12809 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP2C19 P33261 2/20 0.42
SLC22A2 O15244 1/20 0.42
SLC22A1 O15245 1/20 0.42
SLC22A3 O75751 1/20 0.42
ESR1 P03372 1/20 0.42
CHRM2 P08172 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11270890 0.81 ADRA2B (0.55) TSHRALDH1A1AOC3ADRA2BADRA2C
SCHEMBL3331448 0.78 SIGMAR1 (0.44) TSHRALDH1A1AOC3SIGMAR1ADRA2B
SCHEMBL615300 0.76 BCHE (0.48) TSHRALDH1A1AOC3SIGMAR1ADRA2B
SCHEMBL45416 0.76 SIGMAR1 (0.46) TSHRALDH1A1AOC3SIGMAR1ADRA2B
SCHEMBL28540834 0.75 TSHR (0.45) TSHRALDH1A1AOC3SIGMAR1ADRA2B
SCHEMBL44025 0.75 TSHR (0.41) TSHRALDH1A1AOC3SIGMAR1ADRA2B
SCHEMBL44989 0.75 SIGMAR1 (0.41) TSHRALDH1A1AOC3SIGMAR1ADRA2B
SCHEMBL15070152 0.75 CARM1 (0.42) TSHRALDH1A1AOC3SIGMAR1ADRA2B
SCHEMBL3635237 0.75 TSHR (0.54) TSHRALDH1A1AOC3SIGMAR1ADRA2B
SCHEMBL15070151 0.74 SIGMAR1 (0.41) TSHRALDH1A1AOC3SIGMAR1ADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022035852-A1 DECITABINE ANALOGS FOR IMMUNOLOGICAL AND ONCOLOGICAL THERAPY THE JOHNS HOPKINS UNIVERSITY (US) 2022-02-17 WO disclosed